This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Pre-Assessment
  • Activity
  • Post-Test
  • Evaluation
  • Claim Credit
Emerging Role of Biosimilars: Improving Awareness and Addressing Common Concerns

Emerging Role of Biosimilars: Improving Awareness and Addressing Common Concerns

Format

Webcast

Time to Complete

1.50 hours

Released

July 24, 2019

Expires

July 24, 2020
Add to Queue


Maximum Credits

1.50 / AMA PRA Category 1 CreditsTM
1.46 / CNE Contact Hours (1.46 pharmacotherapeutic contact hours)

Accredited Provider

This enduring activity is jointly provided by Talem MedEd and Boston University School of Medicine.

Commercial Supporter

This activity is supported by an educational grant from Pfizer.

Program Description

Biosimilars are designed to increase access to treatment at reduced prescription costs while providing equivalent therapeutic efficacy. Despite their potential benefit on clinical and economic outcomes, the uptake of biosimilars has been slow in the United States. Increased understanding of the similarities and differences between biosimilars and their reference products is needed to help overcome concerns about safety and reservations regarding use of biosimilars. In this CME/CE activity, expert faculty compare biosimilars with their reference biologics in terms of their regulatory pathway of approval and requirements for interchangeability, and discuss strategies to increase biosimilar adoption.

Intended Audience

This activity is designed specifically for primary care clinicians, nurses and other members of the healthcare team.

Educational Objectives

After completing the activity, the participant should be better able to:

  • Recognize the similarities and differences between biosimilars and reference biologics in terms of their development, regulatory pathway of approval, and pharmacovigilance
  • Discuss the role of biosimilars and their impact on access to treatment, cost utility, and patient outcomes
  • Integrate shared decision-making practices to inform and engage patients on biosimilars

Conflicts of Interest Disclosure Policy

Boston University School of Medicine asks all individuals, and their spouses/partners, involved in the development and presentation of Continuing Medical Education (CME) and Continuing Nursing Education (CNE) activities to disclose all relevant financial relationships with commercial interests. This information is disclosed to CME activity participants prior to the start of the educational activity. Boston University School of Medicine has procedures to resolve all conflicts of interest. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals and devices is being discussed.

Faculty

Jonathan Kay, MD (Activity Chair)
Professor of Medicine
Timothy S. and Elaine L. Peterson Chair in Rheumatology
Director of Clinical Research, Division of Rheumatology
University of Massachusetts Medical School
Worcester, MA

Dr. Kay has disclosed the following relationships: consultant for AbbVie Inc., Boehringer Ingelheim GmbH, Celltrion Healthcare Co. Ltd., Merck Sharp & Dohme Corp., Novartis Pharmaceuticals, Pfizer Inc., Roche Laboratories, Inc., Samsung Bioepis, Sandoz Inc., UCB, Inc.; research support (paid to the University of Massachusetts Medical School) from Gilead Sciences Inc., Pfizer Inc., UCB, Inc.

Alissa R. Segal, PharmD, CDE, CDTC, FCCP
Professor of Pharmacy Practice
Program Director of the School of Pharmacy (Boston)
Doctor of Pharmacy Honors Program
MCPHS University
Clinical Pharmacist
Joslin Diabetes Center
Boston, MA

Dr. Segal has no relevant financial conflicts to disclose.

Thomas P. Meehan, MD, MPH (Activity Moderator)
Executive Director, Connecticut Center for Primary Care
Vice President, Research and Medical Education
ProHealth Physicians, part of OptumCare
Farmington, CT

Dr. Meehan has no relevant financial conflicts to disclose.

Accredited Provider Disclosure

The following planning committee members for this activity have no relevant financial relationships to disclose:

Jennifer Britton‐Colonnese, RN, NP, CNE Course Advisor, Boston University School of Medicine
Joanna Krause, MPH, Program Manager, Boston University School of Medicine, CME/CNE
Carmela Townsend, DNP, MS/MBA, RN, Lead Nurse Planner, Boston University School of
Medicine, CME/CNE
Jason M. Worcester, MD, CME Course Director, Boston University School of Medicine
Klara Czobor, Medical Writer, Scientific Affairs, Talem Health, LLC
Erica Rusie, PharmD, Scientific Director, Scientific Affairs, Talem Health, LLC

Credit

1.50

Type

AMA PRA Category 1 Credit(s)TM

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Boston University School of Medicine and Talem MedEd. Boston University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Designation Statement

Boston University School of Medicine designates this enduring activity for a maximum of 1.50 AMA PRA Category 1 CreditsTM .  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit

1.46

Type

CNE Contact Hour(s)

Accreditation Statement

This educational activity has been provided by Continuing Nursing Education Provider Unit, Boston University School of Medicine and jointly provided by Talem MedEd.

Continuing Nursing Education Provider Unit, Boston University School of Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Designation Statement

Contact Hours: 1.46 of which 1.46 is eligible for pharmacology credit

Disclosure of Unlabeled Use

Faculty do not plan on discussing unlabeled/investigational uses of a commercial product.

Disclaimer

THIS CONTINUING MEDICAL EDUCATION PROGRAM IS INTENDED SOLELY FOR EDUCATIONAL PURPOSES FOR QUALIFIED HEALTH CARE PROFESSIONALS. IN NO EVENT SHALL BOSTON UNIVERSITY OR TALEM HEALTH BE LIABLE FOR ANY DECISION MADE OR ACTION TAKEN IN RELIANCE ON THE INFORMATION CONTAINED IN THE PROGRAM. IN NO EVENT SHOULD THE INFORMATION CONTAINED IN THE PROGRAM BE USED AS A SUBSTITUTE FOR PROFESSIONAL CARE. NO PHYSICIAN-PATIENT RELATIONSHIP IS BEING ESTABLISHED.

Copyright Notice Talem MedEd 2019

Instructions

To obtain credit, a score of 66% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this activity, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/Exam History, which you can access at any time.

For any CME or CNE accreditation questions, please email the BUSM CME office at cme@bu.edu.

BUSM CME complies with the ADA and the rules and regulations thereof to make reasonable accommodations for our educational activities. If any participant in this educational activity is in need of accommodations, please contact BUSM CME at 617-358-5005.

SYSTEM REQUIREMENTS

Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Add to Queue